Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

9. Total Valuation & Waterfall LPBI Group Portfolio Valuation

The LPBI Group portfolio represents a mature, debt-free, founder-led collection of intellectual property assets specifically engineered for domain-aware AI in Health. Built over 14 years of continuous expert curation, the portfolio combines one of the largest privately held multimodal biomedical corpora with a complete 22-part Composition of Methods (COM) Tool Factory.

This rare “own-both” advantage — high-provenance data + proprietary methodology — has already demonstrated significant empirical uplift (including 7.9× in oncology causal relationships) and is valued conservatively at a locked midpoint of $650 Million. The valuation incorporates synergistic uplifts from vertical integration, the revival potential of the 13 Hidden Gems, the formal recognition of COM Part 13 and COM Part 21, and the architectural readiness of the portfolio for direct integration into the SpaceXAI ecosystem.

Valuation Breakdown (Key Components)

• Five Primary Trainable Corpuses (Classes I, II, III, V, X)
• 22-part Composition of Methods (COM) – The proprietary Tool Factory and execution infrastructure moat
• 13 Hidden Gems – Each functioning as a ready-made Small Language Model (SLM) foundation
• 15 Subject Matter Data Sets (“Articles of Note” in leading medical fields) – now formally recognized as COM Part 13
• Vertical Integration Moat – Cross-pollination across all asset classes as narrative not a new dollar
• COM Part 21 (Yields Outcomes) – newly formalized measurement and productization layer

• “Additional High-Value Trainable Assets” — inventoried as Asset EXT-C.9 (Category B), including portals EXT-C.9.8–9.11. No itemized Phase-1 price.

Waterfall Chart The following waterfall chart illustrates the overall composition and build-up of the total portfolio valuation under the revised four-part timeline structure (Part A / Part B / Part C / Part D):

Phase-1 Grand Total is $650 M.

• EXT-C.5 = COM Part 21 only. Part B. Category A. Phase-1 line.
• COM 15+21+22 = Utilization Matrix 10, row 10.9. Not a Phase-1 line. Not Combined-with. Not Asset EXT-C.5.
• “Combined-with …” = Column G on the EXT-C.9 parent (four Gallery JPEGs). Not this chart.

Footnote Detailed component valuations are confidential and available only under NDA. The locked enterprise value of the LPBI portfolio is $650 Million.

COM Part 13 and COM Part 21 have been formally inserted into the valuation structure (Part A and Part B respectively). Their specific values remain confidential on this page.

The Unclaimed Credit represents a deliberate conservative adjustment that preserves optionality for a future Phase-2 Valuation Event.

The Founder provided the List of Valuables and development periods but did not determine any valuation figures. All numerical valuations were developed independently by third-party analysis.

Strategic Role in 2026 & Beyond This valuation reflects a high-provenance, causally structured multimodal data moat that is uniquely positioned for Transfer of Ownership. It offers potential acquirers immediate access to one of the only private training corpuses of this depth and quality, capable of powering leadership in AI-driven biomedical discovery.

Additional High-Value Trainable Assets

The inventory also lists LPBI’s expanding set of specialized trainable assets, including dedicated portals (Coronavirus/SARS-CoV-2, Artificial Intelligence in Genomics & Cancer, Cell Therapy & Regenerative Medicine 2026 and Beyond), and other structured multimodal collections. These assets significantly enhance domain-specific performance and represent substantial additional upside beyond the base corpus.

These assets have now been formally inventoried as Asset EXT-C.9 (Other TRAINABLE Data Assets) in Appendix EXT-C.

These portals are inventoried as Asset EXT-C.9 (Category B). They are not added as Phase-1 dollars. No itemized valuation for these assets is disclosed on this page.

While they are part and parcel of the List of Valuables, no itemized valuation for these specific assets is disclosed in this public summary. Full details are available under appropriate confidentiality agreements.

For additional details, see: Valuation Models per Ten Digital IP Asset Classes in LPBI Group’s Portfolio of IP

https://pharmaceuticalintelligence.com/2025/12/08/valuation-models-per-ten-digital-ip-asset-classes-in-lpbi-groups-portfolio-of-ip/